Department of Pediatrics, Stanford University, Stanford, California, USA.
Nat Med. 2011 Oct 9;17(11):1504-8. doi: 10.1038/nm.2473.
Small-cell lung cancer (SCLC) is an aggressive neuroendocrine subtype of lung cancer for which there is no effective treatment. Using a mouse model in which deletion of Rb1 and Trp53 in the lung epithelium of adult mice induces SCLC, we found that the Hedgehog signaling pathway is activated in SCLC cells independently of the lung microenvironment. Constitutive activation of the Hedgehog signaling molecule Smoothened (Smo) promoted the clonogenicity of human SCLC in vitro and the initiation and progression of mouse SCLC in vivo. Reciprocally, deletion of Smo in Rb1 and Trp53-mutant lung epithelial cells strongly suppressed SCLC initiation and progression in mice. Furthermore, pharmacological blockade of Hedgehog signaling inhibited the growth of mouse and human SCLC, most notably following chemotherapy. These findings show a crucial cell-intrinsic role for Hedgehog signaling in the development and maintenance of SCLC and identify Hedgehog pathway inhibition as a therapeutic strategy to slow the progression of disease and delay cancer recurrence in individuals with SCLC.
小细胞肺癌(SCLC)是一种侵袭性的神经内分泌型肺癌,目前尚无有效的治疗方法。我们利用一种成年小鼠肺部上皮细胞中 Rb1 和 Trp53 缺失会诱发 SCLC 的小鼠模型,发现 Hedgehog 信号通路在 SCLC 细胞中被激活,这一现象独立于肺部微环境。Hedgehog 信号分子 Smoothened(Smo)的组成性激活促进了体外人 SCLC 的集落形成能力以及体内小鼠 SCLC 的起始和进展。相反,在 Rb1 和 Trp53 突变的肺部上皮细胞中敲除 Smo,强烈抑制了小鼠 SCLC 的起始和进展。此外,Hedgehog 信号通路的药理学阻断抑制了小鼠和人 SCLC 的生长,尤其是在化疗后。这些发现表明 Hedgehog 信号在 SCLC 的发展和维持中具有重要的细胞内作用,并确定 Hedgehog 通路抑制是一种治疗策略,可以减缓疾病进展并延迟 SCLC 患者的癌症复发。